Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by pericles1on Oct 14, 2010 9:53am

408 Views

Post# 17563235

RE: From the Yahoo board.

Come on Cardu you know Brad as well as anyone, throw out the clock with him.

Ah! the monthly updates on enrollments, at the time that seemed hard to believe, just Brad getting carried away again. With a presentation every couple weeks he has had plenty of opportunity but it's not going to happen. I'm convinced that if we get an enrollment update by Christmas we will be lucky. Since I know Brad from past experience I can't actually say I'm disappointed, it was expected.

Bullboard Posts

Gold vs. bitcoin, where should you invest?